Welcome to our dedicated page for UroGen Pharma Ltd. SEC filings (Ticker: URGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on UroGen Pharma Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into UroGen Pharma Ltd.'s regulatory disclosures and financial reporting.
UroGen Pharma Ltd. (URGN) director James A. Robinson Jr. reported the exercise and settlement of equity awards. On 2026-08-26, he exercised 2,000 Restricted Stock Units, each representing a contingent right to receive one ordinary share, which converted into 2,000 ordinary shares of UroGen.
The derivative RSU position of 2,000 units was fully settled, leaving no RSUs from this award outstanding, and Mr. Robinson’s directly held ordinary shares increased to 8,000 shares following the transaction.
UroGen Pharma Ltd. (URGN) reported that Chief Medical Officer Mark Schoenberg sold 60,677 ordinary shares on 2026-08-20 in an open market or private transaction. The weighted average sale price was $47.05 per share, with prices ranging from $46.30 to $49.70. Following the sale, Schoenberg directly holds 59,086 ordinary shares.
UroGen Pharma Ltd. (symbol URGN) received a Form 144 notice indicating that officer Mark Schoenberg plans sales of common shares under Rule 144, with RBC Capital Markets LLC as the broker. The common stock is listed on Nasdaq. The shares to be sold were acquired through a stock option exercise from the issuer on January 27, 2023. Over the prior three months, Schoenberg reported two Rule 144 sales of UroGen common stock totaling 20,000 shares, for gross proceeds of $400,008.00 on July 9, 2026 and $350,143.00 on June 22, 2026.
UroGen Pharma Ltd. (URGN) reported that its wholly owned subsidiary, UroGen Pharma, Inc., entered into an Option and Research License Agreement with IntraGel Therapeutics, Ltd. on August 18, 2026. UroGen obtained an exclusive option to secure an exclusive, worldwide license to IntraGel’s TumoCure product formulated with IntraGel’s proprietary SRGel platform for treating advanced head and neck cancer, options for additional SRGel-based products designated by UroGen, and a non-exclusive license to research and evaluate the SRGel platform.
In a related transaction, UroGen Pharma Ltd. agreed, under a Securities Purchase Agreement with IntraGel, to invest up to $7,000,000 in IntraGel’s equity securities, aligning its financial commitment with the collaboration’s development and evaluation activities.
The Toronto-Dominion Bank and TD Securities Inc. report beneficial ownership of 3,371,263 ordinary shares of UroGen Pharma Ltd., representing 6.9% of the outstanding class of ordinary shares, par value NIS 0.01 per share.
The Toronto-Dominion Bank has sole voting and dispositive power over 3,269,957 shares, while TD Securities Inc. has sole voting and dispositive power over 101,306 shares. TD Securities Inc. is wholly owned by The Toronto-Dominion Bank. The Toronto-Dominion Bank may be deemed to hold an indirect interest in TD Securities Inc.’s shares through this ownership but expressly disclaims beneficial ownership of those shares except to the extent of its pecuniary interest. The reporting persons also state that nothing in the disclosure should be construed as them acting as part of a group with any other person regarding UroGen Pharma securities.
UroGen Pharma reported sharply higher oncology product sales for the quarter ended June 30, 2026. Net revenue reached $72.5 million, up from $24.2 million a year earlier, driven by Zusduri ($50.4 million) alongside Jelmyto ($22.0 million). Gross profit increased to $65.9 million, and operating results swung to a small income of $0.1 million from a $41.4 million loss. After interest, financing costs and income taxes, net loss narrowed to $14.4 million (loss per share $0.28) versus $49.9 million (loss per share $1.05). For the first half of 2026, revenue was $123.4 million with a net loss of $37.9 million.
At June 30, 2026, UroGen held cash, cash equivalents and marketable securities totaling $108.0 million, plus accounts receivable of $88.8 million, against total liabilities of $385.0 million. Key obligations include a prepaid forward liability of $125.1 million tied to Jelmyto and Zusduri sales and long-term debt of $188.7 million under a Pharmakon term loan maturing in 2030–2031. Shareholders’ deficit was $132.4 million on an accumulated deficit of $997.6 million.
Net cash used in operating activities was $78.3 million for the first six months of 2026. Management states that existing cash and marketable securities are expected to fund operations for more than one year, with future performance heavily dependent on commercialization of Jelmyto and Zusduri.
UroGen Pharma reported strong second-quarter 2026 results, highlighted by the commercial launch of ZUSDURI. Total revenue was $72.5 million, up from $24.2 million a year earlier, including $50.4 million of ZUSDURI revenue. JELMYTO continued to contribute as a marketed product.
Operating performance improved markedly: gross profit reached $65.9 million and operating income turned slightly positive at $0.1 million, while net loss narrowed to $14.4 million, or $0.28 per share, from $49.9 million. Cash, cash equivalents and marketable securities totaled $108.0 million as of June 30, 2026.
The company reiterated 2026 JELMYTO net product revenue guidance of $97–$101 million and raised full-year 2026 operating expense guidance to $260–$270 million, including $20–$24 million of non-cash share-based compensation, reflecting accelerated investment behind ZUSDURI and pipeline candidates UGN-103 and UGN-501. A new U.S. patent allowance is expected to extend IP coverage for ZUSDURI and UGN-103 into July 2044.
UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg reported an open-market sale of 10,000 Ordinary Shares of URGN at a weighted average price of $40.00 per share. The transaction was made pursuant to a duly adopted Rule 10b5-1(c) trading plan and represents the final sale under that plan. Following this sale, Schoenberg holds 119,763 Ordinary Shares directly.
UroGen Pharma Ltd. reported proposed sales of common stock by an affiliate via Form 144. The filing lists two dispositions of 10,000 shares each sold on 05/08/2026 and 06/22/2026 for $300,048 and $350,143, respectively, and references a stock option exercise dated 01/27/2023.
UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg sold 10,000 Ordinary Shares in an open-market transaction at a weighted average price of $35.01 per share, with trades ranging from $35.00 to $35.08, under a pre-adopted Rule 10b5-1(c) trading plan. Following this sale on June 22, 2026, he directly holds 129,763 Ordinary Shares.